Plain-English translation of NCT07269782 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of two medications: HLX43 and . These are given as infusions (through an IV) before you have surgery to remove the cancer. The trial will compare two different doses of HLX43 to see which works best and is safest for people with early-stage lung cancer.
Currently, surgery alone is the main treatment for early-stage lung cancer, but cancer can come back. This trial is testing whether giving these medications before surgery might help destroy cancer cells and improve chances that the cancer won't return.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would receive the two medications as IV infusions every 3 weeks for 3 or 4 cycles (about 9โ12 weeks total). During this time, you would have regular clinic visits for monitoring and blood tests. After finishing the medications, if you remain eligible, you would undergo surgery to remove the cancer. The study team would follow your progress to see how well the treatment worked and check for any side effects.
AI-generated summary from trial data ยท Jun 12, 2026 ยท Not medical advice
China